To ask the Secretary of State for Health and Social Care, what the (a) budget and (b) scope is of the planned Innovative Medicines Fund; what funding will be allocated to (a) promising innovative medicines within or outside the Early Access to Medicines Scheme, (b) medicines for rare diseases and (c) support for research into, rescheduling of and licensing of compounds classified as Schedule 1 under the Misuse of Drugs Regulations 2001.
23 October 2020
Proposals for the Innovative Medicines Fund (IMF) are in development and will take full account of stakeholder views to ensure best use of the Fund. The budget for the fund will be confirmed in due course.
Alongside the IMF, we will continue to support the Early Access to Medicines Scheme, which is a key part of the Government’s commitment to accelerating patient access to innovative, life-changing treatments.
The National Institute for Health Research welcomes funding applications for research into any aspect of human health; it is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.